These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

466 related items for PubMed ID: 25268567

  • 1. Which luteal phase support is better for each IVF stimulation protocol to achieve the highest pregnancy rate? A superiority randomized clinical trial.
    Gizzo S, Andrisani A, Esposito F, Noventa M, Di Gangi S, Angioni S, Litta P, Gangemi M, Nardelli GB.
    Gynecol Endocrinol; 2014; 30(12):902-8. PubMed ID: 25268567
    [Abstract] [Full Text] [Related]

  • 2. Addition of estradiol to progesterone for luteal supplementation in patients stimulated with GnRH antagonist/rFSH for IVF: a randomized controlled trial.
    Fatemi HM, Kolibianakis EM, Camus M, Tournaye H, Donoso P, Papanikolaou E, Devroey P.
    Hum Reprod; 2006 Oct; 21(10):2628-32. PubMed ID: 16857887
    [Abstract] [Full Text] [Related]

  • 3. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Fatemi HM, Polyzos NP, van Vaerenbergh I, Bourgain C, Blockeel C, Alsbjerg B, Papanikolaou EG, Humaidan P.
    Fertil Steril; 2013 Sep; 100(3):742-7. PubMed ID: 23806846
    [Abstract] [Full Text] [Related]

  • 4. Endometrial gene expression in the early luteal phase is impacted by mode of triggering final oocyte maturation in recFSH stimulated and GnRH antagonist co-treated IVF cycles.
    Humaidan P, Van Vaerenbergh I, Bourgain C, Alsbjerg B, Blockeel C, Schuit F, Van Lommel L, Devroey P, Fatemi H.
    Hum Reprod; 2012 Nov; 27(11):3259-72. PubMed ID: 22930004
    [Abstract] [Full Text] [Related]

  • 5. Steroid receptor expression in late follicular phase endometrium in GnRH antagonist IVF cycles is already altered, indicating initiation of early luteal phase transformation in the absence of secretory changes.
    Papanikolaou EG, Bourgain C, Kolibianakis E, Tournaye H, Devroey P.
    Hum Reprod; 2005 Jun; 20(6):1541-7. PubMed ID: 15705618
    [Abstract] [Full Text] [Related]

  • 6. Luteal granulosa cells from natural cycles are more capable of maintaining their viability, steroidogenic activity and LH receptor expression than those of stimulated IVF cycles.
    Bildik G, Akin N, Seyhan A, Esmaeilian Y, Yakin K, Keles I, Balaban B, Ata B, Urman B, Oktem O.
    Hum Reprod; 2019 Feb 01; 34(2):345-355. PubMed ID: 30520979
    [Abstract] [Full Text] [Related]

  • 7. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial.
    Andersen CY, Elbaek HO, Alsbjerg B, Laursen RJ, Povlsen BB, Thomsen L, Humaidan P.
    Hum Reprod; 2015 Oct 01; 30(10):2387-95. PubMed ID: 26209535
    [Abstract] [Full Text] [Related]

  • 8. The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study.
    Engmann L, DiLuigi A, Schmidt D, Benadiva C, Maier D, Nulsen J.
    Fertil Steril; 2008 Mar 01; 89(3):554-61. PubMed ID: 17678651
    [Abstract] [Full Text] [Related]

  • 9. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG, Macklon NS, Eijkemans MJ, Ludwig M, Felberbaum RE, Diedrich K, Bustion S, Loumaye E, Fauser BC.
    J Clin Endocrinol Metab; 2003 Sep 01; 88(9):4186-92. PubMed ID: 12970285
    [Abstract] [Full Text] [Related]

  • 10. Impact of clomiphene citrate during ovarian stimulation on the luteal phase after GnRH agonist trigger.
    Derksen L, Tournaye H, Stoop D, Van Vaerenbergh I, Bourgain C, Polyzos NP, Haentjens P, Blockeel C.
    Reprod Biomed Online; 2014 Mar 01; 28(3):359-68. PubMed ID: 24456700
    [Abstract] [Full Text] [Related]

  • 11. Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol for patients with a history of poor in vitro fertilization outcomes.
    Weitzman VN, Engmann L, DiLuigi A, Maier D, Nulsen J, Benadiva C.
    Fertil Steril; 2009 Jul 01; 92(1):226-30. PubMed ID: 18675961
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
    Krause BT, Ohlinger R.
    Eur J Obstet Gynecol Reprod Biol; 2006 May 01; 126(1):87-92. PubMed ID: 16377065
    [Abstract] [Full Text] [Related]

  • 13. The influence of estradiol/follicle and estradiol/oocyte ratios on the outcome of controlled ovarian stimulation for in vitro fertilization.
    Orvieto R, Zohav E, Scharf S, Rabinson J, Meltcer S, Anteby EY, Homburg R.
    Gynecol Endocrinol; 2007 Feb 01; 23(2):72-5. PubMed ID: 17454155
    [Abstract] [Full Text] [Related]

  • 14. The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation with progesterone or progesterone and estradiol.
    Fatemi HM, Camus M, Kolibianakis EM, Tournaye H, Papanikolaou EG, Donoso P, Devroey P.
    Fertil Steril; 2007 Mar 01; 87(3):504-8. PubMed ID: 17140572
    [Abstract] [Full Text] [Related]

  • 15. Initiation of ovarian stimulation independent of the menstrual cycle: a case-control study.
    Buendgen NK, Schultze-Mosgau A, Cordes T, Diedrich K, Griesinger G.
    Arch Gynecol Obstet; 2013 Oct 01; 288(4):901-4. PubMed ID: 23545834
    [Abstract] [Full Text] [Related]

  • 16. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists.
    Kolibianakis EM, Schultze-Mosgau A, Schroer A, van Steirteghem A, Devroey P, Diedrich K, Griesinger G.
    Hum Reprod; 2005 Oct 01; 20(10):2887-92. PubMed ID: 15979994
    [Abstract] [Full Text] [Related]

  • 17. Estradiol supplementation during the luteal phase may improve the pregnancy rate in patients undergoing in vitro fertilization-embryo transfer cycles.
    Farhi J, Weissman A, Steinfeld Z, Shorer M, Nahum H, Levran D.
    Fertil Steril; 2000 Apr 01; 73(4):761-6. PubMed ID: 10731538
    [Abstract] [Full Text] [Related]

  • 18. IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre-treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study.
    Ye H, Huang GN, Zeng PH, Pei L.
    J Assist Reprod Genet; 2009 Mar 01; 26(2-3):105-11. PubMed ID: 19225876
    [Abstract] [Full Text] [Related]

  • 19. GnRH antagonists in ovarian stimulation for IVF.
    Tarlatzis BC, Fauser BC, Kolibianakis EM, Diedrich K, Rombauts L, Devroey P.
    Hum Reprod Update; 2006 Mar 01; 12(4):333-40. PubMed ID: 16567347
    [Abstract] [Full Text] [Related]

  • 20. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN, Phung HT, Ho MT.
    Hum Reprod; 2015 May 01; 30(5):1188-95. PubMed ID: 25740882
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.